{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T15:03:36Z","timestamp":1774710216029,"version":"3.50.1"},"reference-count":12,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2022,8,31]]},"DOI":"10.5582\/ddt.2022.01046","type":"journal-article","created":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T22:13:01Z","timestamp":1661033581000},"page":"164-168","source":"Crossref","is-referenced-by-count":8,"title":["The clinical significance of dupilumab-induced blood eosinophil elevation in Japanese patients with atopic dermatitis"],"prefix":"10.5582","volume":"16","author":[{"given":"Emi","family":"Tosuji","sequence":"first","affiliation":[{"name":"Department of Dermatology, Wakayama Medical University, Wakayama, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Inaba","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wakayama Medical University, Wakayama, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Muraoka","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wakayama Medical University, Wakayama, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayo","family":"Kunimoto","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wakayama Medical University, Wakayama, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikako","family":"Kaminaka","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wakayama Medical University, Wakayama, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wakayama Medical University, Wakayama, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Jinnin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wakayama Medical University, Wakayama, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Iwaszko M, Bia\u0142y S, Bogunia-Kubik K. Significance of interleukin (IL)-4 and IL-13 in inflammatory arthritis. Cells. 2021; 10:3000.","DOI":"10.3390\/cells10113000"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Paul WE, Zhu J. How are T(H)2-type immune responses initiated and amplified? Nat Rev Immunol. 2010; 10:225-235.","DOI":"10.1038\/nri2735"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA, Group BS. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev. 2010; 9:188-193.","DOI":"10.1016\/j.autrev.2009.10.003"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Eichenfield LF, Tom WL, Chamlin SL, <i>et al<\/i>. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014; 70:338-351.","DOI":"10.1016\/j.jaad.2013.10.010"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015; 172:1353-1357.","DOI":"10.1111\/bjd.13662"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Strober B, Mallya UG, Yang M, Ganguli S, Gadkari A, Wang J, Sierka D, Delevry D, Kimball AB. Treatment outcomes associated with dupilumab use in patients with atopic dermatitis: 1-year results from the RELIEVE-AD study. JAMA Dermatol. 2022; 158:142-150.","DOI":"10.1001\/jamadermatol.2021.4778"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Wollenberg A, Beck LA, Blauvelt A, <i>et al.<\/i> Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol. 2020; 182:1120-1135.","DOI":"10.1111\/bjd.18434"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Webb DC, McKenzie AN, Koskinen AM, Yang M, Mattes J, Foster PS. Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol. 2000; 165:108-113.","DOI":"10.4049\/jimmunol.165.1.108"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Akinlade B, Guttman-Yassky E, de Bruin-Weller M, <i>et al<\/i>. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019; 181:459-473.","DOI":"10.1111\/bjd.17869"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Bakker DS, Ariens LFM, van Luijk C, van der Schaft J, Thijs JL, Schuttelaar MLA, van Wijk F, Knol EF, Balak DMW, van Dijk MR, de Bruin-Weller MS. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol. 2019; 180:1248-1249.","DOI":"10.1111\/bjd.17538"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Voorberg AN, den Dunnen WFA, Wijdh RHJ, de Bruin-Weller MS, Schuttelaar MLA. Recurrence of conjunctival goblet cells after discontinuation of dupilumab in a patient with dupilumab-related conjunctivitis. J Eur Acad Dermatol Venereol. 2020; 34:e64-e66.","DOI":"10.1111\/jdv.15914"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Katsuta M, Ishiuji Y, Matsuzaki H, Yasuda KI, Kharma B, Nobeyama Y, Hayashi T, Tokura Y, Asahina A. Transient increase in circulating basophils and eosinophils in dupilumab-associated conjunctivitis in patients with atopic dermatitis. Acta Derm Venereol. 2021; 101:adv00483.","DOI":"10.2340\/00015555-3842"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/16\/4\/16_2022.01046\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T04:57:27Z","timestamp":1663390647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/16\/4\/16_2022.01046\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2022.01046","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,31]]},"article-number":"2022.01046"}}